Story preview
Topics in this story
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
10
in the last 3 days
First reported
3 days ago
9 outlets since
Countries
9 other outlets reported this story in the last 3 days.
MSFT was also the top gainer among the Magnificent Seven stocks in Q3.
Bank of America analyst Alec Stranahan raised his price target on TG Therapeutics to $20 from $17 but kept an ‘Underperform’ rating on the shares.
Piper Sandler just set one of Wall Street's boldest Microsoft targets, and the reasoning goes well beyond last quarter's blowout earnings. The case hinges on a new enterprise licensing tier that two months in is already reshaping how Microsoft charges its biggest customers.